Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK)
HKD 1.3
(-2.99%)
HKD 1.3
(-2.99%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -933.21 Million CNY | 17.84% |
| 2022 | -1.13 Billion CNY | 25.3% |
| 2021 | -1.52 Billion CNY | 5.96% |
| 2020 | -1.61 Billion CNY | -450.27% |
| 2019 | -293.81 Million CNY | 27.52% |
| 2018 | -405.36 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -996.39 Million CNY | -6.77% |
| 2024 Q2 | -996.39 Million CNY | 13.49% |
| 2023 Q1 | -1.1 Billion CNY | 2.28% |
| 2023 FY | -933.21 Million CNY | 17.84% |
| 2023 Q4 | -933.21 Million CNY | 2.0% |
| 2023 Q3 | -952.26 Million CNY | 13.05% |
| 2023 Q2 | -1.09 Billion CNY | 1.32% |
| 2022 Q3 | -1.16 Billion CNY | 20.05% |
| 2022 Q2 | -1.45 Billion CNY | 0.69% |
| 2022 Q1 | -1.46 Billion CNY | 3.58% |
| 2022 FY | -1.13 Billion CNY | 25.3% |
| 2022 Q4 | -1.13 Billion CNY | 2.42% |
| 2021 Q3 | -1.53 Billion CNY | 4.0% |
| 2021 Q4 | -1.52 Billion CNY | 1.0% |
| 2021 Q1 | -1.6 Billion CNY | 0.43% |
| 2021 FY | -1.52 Billion CNY | 5.96% |
| 2021 Q2 | -1.59 Billion CNY | 0.63% |
| 2020 FY | -1.61 Billion CNY | -450.27% |
| 2020 Q4 | -1.61 Billion CNY | 0.53% |
| 2020 Q3 | -1.62 Billion CNY | -320.66% |
| 2020 Q2 | -386.39 Million CNY | 2.16% |
| 2020 Q1 | -394.92 Million CNY | -34.41% |
| 2019 FY | -293.81 Million CNY | 27.52% |
| 2019 Q1 | 420.83 Million CNY | 0.0% |
| 2019 Q3 | -291.05 Million CNY | 0.0% |
| 2019 Q4 | -293.81 Million CNY | -0.95% |
| 2018 FY | -405.36 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | -76.36 Million HKD | -1121.978% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.26 Billion HKD | 117.719% |